Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Finished Goods: 2015-2025

Historic Finished Goods for Amphastar Pharmaceuticals (AMPH) over the last 9 years, with Sep 2025 value amounting to $37.7 million.

  • Amphastar Pharmaceuticals' Finished Goods rose 11.70% to $37.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.7 million, marking a year-over-year increase of 11.70%. This contributed to the annual value of $39.4 million for FY2024, which is 58.14% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Finished Goods is $37.7 million, which was down 9.34% from $41.6 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Finished Goods ranged from a high of $41.6 million in Q2 2025 and a low of $14.5 million during Q1 2022.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Finished Goods value was $30.8 million (recorded in 2024), while the average stood at $32.1 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Finished Goods decreased by 22.62% in 2022 and then skyrocketed by 91.35% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Finished Goods (Quarterly) stood at $17.7 million in 2021, then grew by 6.97% to $18.9 million in 2022, then skyrocketed by 31.99% to $24.9 million in 2023, then soared by 58.14% to $39.4 million in 2024, then increased by 11.70% to $37.7 million in 2025.
  • Its Finished Goods was $37.7 million in Q3 2025, compared to $41.6 million in Q2 2025 and $38.4 million in Q1 2025.